Erratum to: Treatment with mefolinate (5-methyltetrahydrofolate), but not folic acid or folinic acid, leads to measurable 5-methyltetrahydrofolate in cerebrospinal fluid in methylenetetrahydrofolate reductase deficiency (JIMD Reports, (2016) 29, (103-107), 10.1007/8904_2016_529);Treatment with mefolinate (5-methyltetrahydrofolate), but not folic acid or folinic acid, leads to measurable 5-methyltetrahydrofolate in cerebrospinal fluid in methylenetetrahydrofolate reductase deficiency

JIMD Reports

Volumn 29, Issue , 2016, Pages 103-107

  Knowles, L ^a   Morris, A A M ^a   Walter, J H ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Folinic Acid; Homocysteine Level; Methylmalonic Acid; Normal Vaginal Delivery; Sodium Valproate

Indexed keywords

EID: 85007326377     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2016_574     Document Type: Erratum

References (13)

1. Burda P, Schafer A, Suormala T et al (2015) Insights into severe 5,10-methylenetetrahydrofolate reductase deficiency: molecular genetic and enzymatic characterization of 76 patients. Hum Mutat 36:611–621
2. Clayton PT, Smith I, Harding B, Hyland K, Leonard JV, Leeming RJ (1986) Subacute combined degeneration of the cord, dementia and parkinsonism due to an inborn error of folate metabolism. J Neurol Neurosurg Psychiatry 49:920–927
3. Diekman EF, de Koning TJ, Verhoeven-Duif NM, Rovers MM, van Hasselt PM (2014) Survival and psychomotor development with early betaine treatment in patients with severe methylenetetrahydrofolate reductase deficiency. JAMA Neurol 71:188–194
4. El-Gharbawy AH, Smith EC, Bottiglieri T, Hyland K, Young SP, Koeberl D (2011) Why 5-methyltetrahydrofolate may be preferred to folinic acid in severe MTHFR deficiency complicated by cerebral folate deficiency. Results of an “n-1-clinical trial”. Mol Genet Metab 102:278–279
5. Huemer M, Mulder-Bleile R, Burda P et al (2015) Clinical pattern, mutations and in vitro residual activity in 33 patients with severe 5, 10 methylenetetrahydrofolate reductase (MTHFR) deficiency. J Inherit Metab Dis 39:115–124
6. Jadavji NM, Deng L, Leclerc D et al (2012) Severe methylenetetrahydrofolate reductase deficiency in mice results in behavioral anomalies with morphological and biochemical changes in hippocampus. Mol Genet Metab 106:149–159
7. Kempson SA, Zhou Y, Danbolt NC (2014) The betaine/GABA transporter and betaine: roles in brain, kidney, and liver. Front Physiol 5:159
8. Levitt M, Nixon PF, Pincus JH, Bertino JR (1971) Transport characteristics of folates in cerebrospinal fluid; a study utilizing doubly labeled 5-methyltetrahydrofolate and 5-formyltetrahydro-folate. J Clin Invest 50:1301–1308
9. Li D, Karp N, Wu Q et al (2008) Mefolinate (5-methyltetrahydrofo-late), but not folic acid, decreases mortality in an animal model of severe methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 31:403–411
10. Schiff M, Benoist JF, Tilea B, Royer N, Giraudier S, Ogier de Baulny H (2011) Isolated remethylation disorders: do our treatments benefit patients? J Inherit Metab Dis 34:137–145
11. Strauss KA, Morton DH, Puffenberger EG et al (2007) Prevention of brain disease from severe 5,10-methylenetetrahydrofolate reductase deficiency. Mol Genet Metab 91:165–175
12. Torres A, Newton SA, Crompton B et al (2015) CSF 5-methyltetrahydrofolate serial monitoring to guide treatment of congenital folate malabsorption due to proton-coupled folate transporter (PCFT) deficiency. JIMD Rep 24:91–96
13. Watkins D, Rosenblatt D, Fowler B (2012) Disorders of cobalamin and folate transport and metabolism. In: Saudubray J-M, van den Berghe G, Walter J (eds) Inborn metabolic diseases. Springer, Berlin/Heidelberg, pp 385–402